Human T-lymphotropic Virus Type 1 and Type 2 Seroprevalence, Incidence, and Residual Transfusion Risk Among Blood Donors in Brazil During 2007-2009

Overview

Journal AIDS Res Hum Retroviruses

Publisher Mary Ann Liebert

Specialty Infectious Diseases

Date 2012 Feb 14

PMID 22324906

Citations 25

Authors

Anna Barbara F Carneiro-Proietti

Ester C Sabino

Silvana Leao

Nanci A Salles

Paula Loureiro

Moussa Sarr

David Wright

Michael Busch

Fernando A Proietti

Edward L Murphy

Affiliations

Soon will be listed here.

Abstract

Human T-lymphotropic virus type 1/2 (HTLV-1/2) infection is endemic in Brazil but representative donor prevalence and incidence data are lacking. All blood donations (2007-2009) from three blood centers in Brazil were studied. Samples reactive on one HTLV screening test (EIA) were retested with a different EIA; dual EIA reactivity correlated strongly with a confirmatory Western blot. Prevalence, incidence, and residual transfusion risk were calculated. Among 281,760 first-time donors, 363 were positive for HTLV on both EIAs (135 per 10(5), 95% CI 122-150). Prevalence differed considerably by region, from 83 to 222 per 10(5). Overall incidence rate was 3.6/10(5) person-years and residual transfusion risk was 5.0/10(6) per blood unit transfused. The logistic regression model showed significant associations with: age [adjusted odds ratio (aOR)=5.23 for age 50+ vs. <20], female sex (aOR=1.97), black (aOR=2.70 vs. white), and mixed skin colors (aOR=1.78 vs. white), and inversely with education (aOR=0.49, college vs. less than high school). HTLV testing with a dual-EIA strategy is feasible and can be useful in areas with low resources. Incidence and residual risk of HTLV-1 transmission by transfusion were relatively high and could be reduced by improving donor recruitment and selection in high prevalence areas. Blood center data may contribute to surveillance for HTLV infection.

Citing Articles

How do socioeconomic determinants of health affect the likelihood of living with HTLV-1 globally? A systematic review with meta-analysis.

Ramesh N, Cockbain B, Taylor G, Rosadas C Front Public Health. 2024; 12:1298308.

PMID: 38327581 PMC: 10848500. DOI: 10.3389/fpubh.2024.1298308.

Blood Center Testing Allows the Detection and Rapid Treatment of Acute and Recent HIV Infection.

van den Berg K, Vermeulen M, Bakkour S, Stone M, Jacobs G, Nyoni C Viruses. 2022; 14(11).

PMID: 36366424 PMC: 9698357. DOI: 10.3390/v14112326.

Multi-Epitope Protein as a Tool of Serological Diagnostic Development for HTLV-1 and HTLV-2 Infections.

Franco G, da Rocha A, Cox L, Daian E Silva D, da Silveira E Santos D, Martins M Front Public Health. 2022; 10:884701.

PMID: 35677763 PMC: 9168532. DOI: 10.3389/fpubh.2022.884701.

Prevalence and Risk Factors for Human T-Cell Lymphotropic Virus (HTLV) in Blood Donors in Brazil-A 10-Year Study (2007-2016).

Miranda C, Utsch-Goncalves D, Piassi F, Loureiro P, Gomes I, Ribeiro M Front Med (Lausanne). 2022; 9:844265.

PMID: 35355612 PMC: 8959844. DOI: 10.3389/fmed.2022.844265.

Brazilian Protocol for Sexually Transmitted Infections 2020: human T-cell lymphotropic virus (HTLV) infection.

Rosadas C, Brites C, Arakaki-Sanchez D, Casseb J, Ishak R Rev Soc Bras Med Trop. 2021; 54(suppl 1):e2020605.

PMID: 34008723 PMC: 8210483. DOI: 10.1590/0037-8682-605-2020.

References

Galvao-Castro B, Loures L, Rodriques L, Sereno A, Ferreira Junior O, Franco L . Distribution of human T-lymphotropic virus type I among blood donors: a nationwide Brazilian study. Transfusion. 1997; 37(2):242-3. DOI: 10.1046/j.1537-2995.1997.37297203532.x. View

Goncalves D, Proietti F, Ribas J, Araujo M, Pinheiro S, Guedes A . Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev. 2010; 23(3):577-89. PMC: 2901658. DOI: 10.1128/CMR.00063-09. View

Schreiber G, Busch M, Kleinman S, Korelitz J . The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996; 334(26):1685-90. DOI: 10.1056/NEJM199606273342601. View

Taylor G . The epidemiology of HTLV-I in Europe. J Acquir Immune Defic Syndr Hum Retrovirol. 1996; 13 Suppl 1:S8-14. DOI: 10.1097/00042560-199600001-00003. View

Murphy E, Figueroa J, Gibbs W, Cranston B, Malley K, Bodner A . Human T-lymphotropic virus type I (HTLV-I) seroprevalence in Jamaica. I. Demographic determinants. Am J Epidemiol. 1991; 133(11):1114-24. DOI: 10.1093/oxfordjournals.aje.a115824. View

Roucoux D, Murphy E . The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev. 2004; 6(3):144-54. View

Carneiro-Proietti A, Catalan-Soares B, Castro-Costa C, Murphy E, Sabino E, Hisada M . HTLV in the Americas: challenges and perspectives. Rev Panam Salud Publica. 2006; 19(1):44-53. DOI: 10.1590/s1020-49892006000100007. View

Andrade R, Ribeiro M, Namen-Lopes M, Silva S, Basques F, Ribas J . Evaluation of the use of real-time PCR for human T cell lymphotropic virus 1 and 2 as a confirmatory test in screening for blood donors. Rev Soc Bras Med Trop. 2010; 43(2):111-5. DOI: 10.1590/s0037-86822010000200001. View

Manns A, Hisada M, La Grenade L . Human T-lymphotropic virus type I infection. Lancet. 1999; 353(9168):1951-8. DOI: 10.1016/s0140-6736(98)09460-4. View

10.

Oliveira C, Loureiro F, de Bastos M, Proietti F, Carneiro-Proietti A . Blood donor deferral in Minas Gerais State, Brazil: blood centers as sentinels of urban population health. Transfusion. 2009; 49(5):851-7. DOI: 10.1111/j.1537-2995.2008.02062.x. View

11.

Kalyanaraman V, Sarngadharan M, Robert-Guroff M, Miyoshi I, Golde D, Gallo R . A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 1982; 218(4572):571-3. DOI: 10.1126/science.6981847. View

12.

Wiktor S, Alexander S, Shaw G, Weiss S, Murphy E, Wilks R . Distinguishing between HTLV-I and HTLV-II by western blot. Lancet. 1990; 335(8704):1533. DOI: 10.1016/0140-6736(90)93078-4. View

13.

Murphy E, Watanabe K, Nass C, Ownby H, Williams A, Nemo G . Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis. 1999; 180(6):1777-83. DOI: 10.1086/315139. View

14.

Morimoto H, Morimoto A, Reiche E, Ueda L, Matsuo T, Vissoci Reiche F . Difficulties in the diagnosis of HTLV-2 infection in HIV/AIDS patients from Brazil: comparative performances of serologic and molecular assays, and detection of HTLV-2b subtype. Rev Inst Med Trop Sao Paulo. 2007; 49(4):225-30. DOI: 10.1590/s0036-46652007000400006. View

15.

Tseliou P, Spanakis N, Spiliotakara A, Politis C, Legakis N, Tsakris A . HTLV-I and -II in southwestern Greece. Transfusion. 2003; 43(11):1641-2. DOI: 10.1046/j.1537-2995.2003.00569.x. View

16.

Glynn S, Kleinman S, Schreiber G, Busch M, Wright D, Smith J . Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA. 2000; 284(2):229-35. DOI: 10.1001/jama.284.2.229. View

17.

Carneiro-Proietti A, Ribas J, Catalan-Soares B, Martins M, Brito-Melo G, Martins-Filho O . [Infection and disease caused by the human T cell lymphotropic viruses type I and II in Brazil]. Rev Soc Bras Med Trop. 2003; 35(5):499-508. DOI: 10.1590/s0037-86822002000500013. View

18.

Gotuzzo E, Arango C, Isturiz R . Human T-cell lymphotropic virus-I in Latin America. Infect Dis Clin North Am. 2000; 14(1):211-39, x-xi. DOI: 10.1016/s0891-5520(05)70225-7. View

19.

Catalan-Soares B, Carneiro-Proietti A, Proietti F . Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saude Publica. 2005; 21(3):926-31. DOI: 10.1590/s0102-311x2005000300027. View

20.

Biswas H, Kaidarova Z, Garratty G, Gibble J, Newman B, Smith J . Increased all-cause and cancer mortality in HTLV-II infection. J Acquir Immune Defic Syndr. 2010; 54(3):290-6. PMC: 2891114. DOI: 10.1097/QAI.0b013e3181cc5481. View